Crispr Therapeutics AG (CRSP) — Cash Flow Reinvestment Rate
Crispr Therapeutics AG (CRSP) has a Cash Flow Reinvestment Rate of 0.90x as of March 2024, reinvesting $98.52 Million (capex $721.00K plus investments $-97.80 Million) from operating cash flow of $109.75 Million. See CRSP cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Crispr Therapeutics AG Cash Flow Reinvestment Rate (2015–2021)
Historical reinvestment intensity for Crispr Therapeutics AG across 3 annual periods. For the full cash flow conversion analysis, see CRSP cash flow conversion.
Annual Cash Flow Reinvestment Rate for Crispr Therapeutics AG (2015–2021)
Year-by-year capital reinvestment analysis for Crispr Therapeutics AG. See CRSP FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 1.92x | $1.04 Billion | $538.97 Million | $81.70 Million | ▲ +1259.5% |
| 2019 | 0.14x | $8.01 Million | $56.68 Million | $6.68 Million | ▲ +569.7% |
| 2015 | 0.02x | $1.25 Million | $59.43 Million | $1.15 Million | — |